Nalbuphine and morphine — Competitive Intelligence Brief

Nalbuphine and morphine (Nalbuphine and morphine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination. Area: Pain management.

marketed Opioid analgesic combination Opioid receptors (mu, kappa, delta) Pain management Small molecule

Target snapshot

Nalbuphine and morphine (Nalbuphine and morphine) — National Taiwan University Hospital. Nalbuphine and morphine are opioid agonists that bind to opioid receptors in the central nervous system to produce analgesia and pain relief.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nalbuphine and morphine TARGET	Nalbuphine and morphine	National Taiwan University Hospital	marketed	Opioid analgesic combination	Opioid receptors (mu, kappa, delta)
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
metoprolol plus morphine	metoprolol plus morphine	Sahlgrenska University Hospital	marketed	Beta-blocker plus opioid analgesic combination	Beta-1 adrenergic receptor; mu-opioid receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Tylenol with codeine	Tylenol with codeine	National Center for Complementary and Integrative Health (NCCIH)	marketed	Opioid analgesic combination	Mu opioid receptor (codeine); cyclooxygenase enzymes (acetaminophen)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Acetaminophen-Hydrocodone	Acetaminophen-Hydrocodone	Le Bonheur Children's Hospital	marketed	Opioid analgesic combination	Mu opioid receptor (hydrocodone component); prostaglandin synthesis inhibition (acetaminophen component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination class)

1. VA Office of Research and Development · 3 drugs in this class
2. Rothman Institute Orthopaedics · 2 drugs in this class
3. Labopharm Inc. · 2 drugs in this class
4. University of Rochester · 2 drugs in this class
5. Montefiore Medical Center · 2 drugs in this class
6. Maastricht University Medical Center · 2 drugs in this class
7. Henry Ford Health System · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Albert Einstein College of Medicine · 1 drug in this class
10. Johnson & Johnson Taiwan Ltd · 1 drug in this class